Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study.

Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Tarantino G, Scarpa R.

Arthritis Res Ther. 2012 Oct 4;14(5):R211. doi: 10.1186/ar4049.

2.

Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.

Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, Di Minno G, Tarantino G; CaRRDS Study Group.

J Rheumatol. 2012 May;39(5):1042-6. doi: 10.3899/jrheum.111391. Epub 2012 Mar 15.

PMID:
22422493
3.

Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.

Iervolino S, Di Minno MN, Peluso R, Lofrano M, Russolillo A, Di Minno G, Scarpa R.

J Rheumatol. 2012 Mar;39(3):568-73. doi: 10.3899/jrheum.110763. Epub 2012 Jan 15.

PMID:
22247361
4.

Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis.

di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, di Minno G.

Arthritis Care Res (Hoboken). 2013 Jan;65(1):141-7. doi: 10.1002/acr.21711.

5.

Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.

Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.

Scand J Rheumatol. 2015 May;44(3):192-9. doi: 10.3109/03009742.2014.962081. Epub 2015 Jan 7.

PMID:
25564882
6.

Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments.

Di Minno MN, Iervolino S, Peluso R, Di Minno A, Ambrosino P, Scarpa R; CaRRDs Study Group.

J Rheumatol. 2014 Apr;41(4):714-22. doi: 10.3899/jrheum.130850. Epub 2014 Feb 15.

PMID:
24532831
7.

Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.

Perrotta FM, Marchesoni A, Lubrano E.

J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805. Epub 2015 Dec 15.

PMID:
26669925
8.

Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.

Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R; CaRRDs Study Group.

Ann Rheum Dis. 2014 Jun;73(6):1157-62. doi: 10.1136/annrheumdis-2012-202812. Epub 2013 Jun 14.

9.

Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis.

Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ, Gladman DD.

Arthritis Care Res (Hoboken). 2015 May;67(6):842-7. doi: 10.1002/acr.22529.

10.

Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.

Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group.

Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):705-12. doi: 10.1161/ATVBAHA.110.214585. Epub 2011 Jan 6.

11.

Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R.

Immunol Res. 2015 Feb;61(1-2):147-53. doi: 10.1007/s12026-014-8595-z.

PMID:
25395342
12.
13.

Platelet reactivity and disease activity in subjects with psoriatic arthritis.

Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G.

J Rheumatol. 2012 Feb;39(2):334-6. doi: 10.3899/jrheum.110741. Epub 2011 Dec 15.

PMID:
22174208
14.

Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.

Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, Lindegaard HM, Holland-Fischer M, Nordin H, Jensen DV, Olsen CH, Hetland ML.

Arthritis Rheum. 2013 May;65(5):1213-23. doi: 10.1002/art.37876.

15.

Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis.

Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD.

Ann Rheum Dis. 2015 May;74(5):813-7. doi: 10.1136/annrheumdis-2013-204448. Epub 2014 Jan 15.

PMID:
24431392
16.

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register.

Arthritis Res Ther. 2009;11(2):R52. doi: 10.1186/ar2670. Epub 2009 Apr 8.

17.

Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study.

Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G, Ortolan A, Frallonardo P, Faggin E, Plebani M, Zaninotto M, Lorenzin M, Pauletto P, Doria A.

Joint Bone Spine. 2014 Oct;81(5):421-5. doi: 10.1016/j.jbspin.2014.02.005. Epub 2014 Apr 2.

PMID:
24703399
18.

Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?

Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A.

J Rheumatol. 2015 Dec;42(12):2332-8. doi: 10.3899/jrheum.150595. Epub 2015 Nov 1.

PMID:
26523033
19.

Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort.

Eder L, Chandran V, Schentag CT, Shen H, Cook RJ, Gladman DD.

Rheumatology (Oxford). 2010 Jul;49(7):1361-6. doi: 10.1093/rheumatology/keq091. Epub 2010 Apr 12.

PMID:
20385615
20.

Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.

Stober C, Ye W, Guruparan T, Htut E, Clunie G, Jadon D.

Rheumatology (Oxford). 2018 Jan 1;57(1):158-163. doi: 10.1093/rheumatology/kex387.

PMID:
29077973

Supplemental Content

Support Center